A device for mass transfer between blood and a transfer medium, in particular a gas/gas mixture, includes a chamber through which blood can flow and in which a plurality of mass-permeable hollow fibers of at least one hollow fiber mat, in which the hollow fibers are held at a spacing by way of warp threads, are disposed in the form of a wound or folded hollow fiber package, wherein a transfer medium is able to flow through, and blood is able to flow around, the hollow fibers, and wherein the density of hollow fibers varies locally in the hollow fiber package in the cross-section perpendicular to length of the hollow fibers. Hollow fiber packages and methods of manufacturing thereof are provided in which the hollow fibers are held at a spacing by warp threads, in which the spacing between adjoining hollow fibers is locally increased, in particular compared to a predominantly equidistant spacing between the hollow fibers.

A system for lung assist includes a plurality of fiber bundle sections which includes a fiber bundle housing defining a fiber bundle compartment with a fiber bundle positioned within. The fiber bundle includes a plurality of hollow gas permeable fibers. The fiber bundle housing further includes a gas inlet in fluid connection with the fiber bundle housing and in fluid connection with inlets of the plurality of hollow gas permeable fibers, a gas outlet in fluid connection with the housing and in fluid connection with outlets of the plurality of hollow gas permeable fibers, and a blood outlet in fluid connection with a first end of the fiber bundle. The system further includes a base section including a housing including a pressurizing compartment, a pressurizing mechanism within the pressurizing compartment, a blood inlet in fluid connection with the pressurizing compartment and a conduit.

According to some embodiments, a system may treat blood outside the body of a patient. The system may include one or more pumps configured to pump blood in a fluid flow path at a collective rate over 5 liters per minute. The system may include one or more heat exchangers operable to heat at least a portion of the blood to a temperature of at least 42 degrees Celsius and to allow the blood to cool one or more degrees following heating. The system may include one or more convection dialysis modules configured to perform convection dialysis on at least a portion of the blood at least after the one or more heat exchangers allow the blood to cool one or more degrees.

Extracorporeal blood flow circuit devices can be used during medical procedures such as on-pump open-heart surgery. For example, extracorporeal heat exchange and oxygenation devices can be used to facilitate surgical procedures such as coronary artery bypass grafting. In some embodiments, such an oxygenation device can include an integrated air removal structure. In particular embodiments, the air removal structure can comprise one or more porous hollow fibers.

There is provided an introducer system for percutaneously delivering a first and a second medical device to a patient. The system may comprise an introducer sheath having a longitudinal axis and a lumen formed therein. The system may also comprise a bifurcated hub coupled to a proximal end of the sheath. The hub may comprise a first arm having a first lumen and a first hemostasis valve for the passage of the first medical device. The hub may also comprise a second arm coupled to the first arm and having a second lumen and a second hemostasis valve for the passage of the second medical device. Further, the hub may comprise a connection port such that the first lumen and the second lumen are in communication with the lumen of the introducer sheath for the passage of at least one of the first and second medical devices through the introducer sheath for delivery to the patient.

A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors dissolved in a non-toxic semifluorinated alkane, the patient having one or more respiratory tract inflammatory diseases, the one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient, and the semifluorinated alkane evaporating quickly upon administration to the patient so as to leave the biocompatible drug at a desired treatment location. The administration of the biocompatible drug to the patient treats the one or more respiratory tract inflammatory diseases, reduces the symptoms associated with the one or more respiratory tract inflammatory diseases, and/or alleviates one or more respiratory tract inflammatory diseases.

A combined bio-artificial liver support system, includes branch tubes that are connected in sequence: a blood input branch tube, an upstream tail end, a first plasma separation branch tube comprising at least a first plasma separator, a non-biological purification branch tube comprising at least a plasma perfusion device and a bilirubin adsorber, a biological purification branch tube comprising at least a hepatocyte culture cartridge assembly, and a plasma return branch tube, a downstream tail end of which is set as a blood output end.

Membrane oxygenators useful in a variety of medical situations, including various short-term procedures and relatively longer-term life support, and components of membrane-based oxygenators, such as conditioning modules for exchanging oxygen for carbon dioxide during extracorporeal conditioning of blood, are described. A conditioning module includes a plurality of mats of hollow fibers and a potting material disposed throughout the peripheral edges of the mats to create a circumferential seal that defines a passageway through the plurality of fiber mats having a substantially circular cross-sectional shape. The circumferential seal defines an effective fiber length for each of the hollow fibers. A resisting member is disposed across the proximal ends of at least some of the hollow fibers and is adapted to resist fluid flow into each of the hollow fibers based on the effective fiber length of the particular hollow fiber.

The present disclosure provides extracorporeal membrane oxygenation (ECMO) apparatuses treated to comprise lubricating liquid surfaces, hydrophobic or omniphobic surfaces, and/or fluid and solid repellant slippery surfaces that do not stimulate clotting and thrombus formation to the same degree as do the untreated surfaces. The apparatuses permit ECMO procedures to be conducted using less anticoagulant and/or antiplatelet medications than is possible with untreated apparatuses. Also described are methods of using the treated apparatuses to accomplish ECMO procedures on subjects (e.g., human patients) and upon perfused organs.

The present disclosure concerns embodiments of multi-lumen cannulae that can be used in various different medical procedures. The multi-lumen cannulae can comprise an elongated body comprising multiple different ports that connect to various different sidewall lumens contained within the elongated body. The multi-lumen cannulae can also comprise a central lumen that extends through the entire elongated body and can be fluidly connected to the various different sidewall lumens. The multi-lumen cannulae can further comprise two balloons on an exterior of the elongated body, which can be used to isolate a right atrium of a patient's heart.